Welcome to our dedicated page for Clene news (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene stock.
Clene Inc. reports developments as a late clinical-stage biopharmaceutical company developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Through Clene Nanomedicine Inc., the company focuses on improving mitochondrial health and protecting neuronal function in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease.
Recurring news centers on CNM-Au8®, an investigational nanocrystal suspension designed to target mitochondrial function and the NAD pathway while reducing oxidative stress. Company updates include ALS biomarker and expanded-access data, FDA meeting and regulatory communications, operating and financial results, registered direct financing activity, shareholder communications, voting matters and investor-conference presentations.
Clene Inc. (NASDAQ: CLNN) announced that its subsidiary received a Notice of Allowance from the USPTO for a patent regarding the use of its gold nanocrystals, CNM-Au8, in treating Multiple Sclerosis (MS). This patent expands Clene's intellectual property, which now includes over 130 issued and pending patents. CNM-Au8 is being tested in Phase 2 and 3 trials for MS and Amyotrophic lateral sclerosis (ALS), targeting an estimated $23 billion treatment market. Interim results from ongoing studies show potential improvements in CNS bioenergetic metabolites.
Clene Inc. (NASDAQ: CLNN) completed its merger with Tottenham Acquisition I Limited, effective December 31, 2020, providing approximately $31.9 million in funding, including $22.4 million from PIPE financing. Clene's clinical pipeline includes ongoing Phase 3 and multiple Phase 2 studies targeting neurodegenerative diseases such as ALS, MS, and Parkinson’s disease. The company aims to leverage its nanocatalysis technology for innovative treatments. Interim data from recent trials indicate promising outcomes, positioning Clene for potential growth in this high-need medical area.